Ambeed.cn

首页 / 抑制剂/激动剂 / G蛋白偶联受体/G蛋白 / GPCR / Fasiglifam

Fasiglifam {[allProObj[0].p_purity_real_show]}

货号:A690887 同义名: Tak-875

TAK-875 is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 0.072 μM.

Fasiglifam 化学结构 CAS号:1000413-72-8
Fasiglifam 化学结构
CAS号:1000413-72-8
Fasiglifam 3D分子结构
CAS号:1000413-72-8
Fasiglifam 化学结构 CAS号:1000413-72-8
Fasiglifam 3D分子结构 CAS号:1000413-72-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Fasiglifam 纯度/质量文件 产品仅供科研

货号:A690887 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

更多 >

Fasiglifam 生物活性

描述 GPR40 is one of the G protein-coupled receptors predominantly expressed in pancreatic β-cells, which mediates enhancement of glucose-stimulated insulin secretion by free fatty acids. TAK-875 is a potent, selective, and orally bioavailable anago-allosteric modulator of hGPR40 with EC50 value of 14nM in a FLIPR assay. TAK-875 can stimulate glucose-dependent insulin secretion, making it act in a unique mode for the treatment of type-2 diabetes mellitus. Single oral dosing of TAK-875 at dose of 3mg/kg, at 1h prior to the oral glucose challenge, reduced the blood glucose excursion and augmented insulin secretion in female Wistar fatty rats. Six-week treatment with combination of TAK-875 (10 mg/kg, b.i.d.) with metformin (50 mg·kg−1, q.d.) significantly potentiate their effect alone on decrease of glycosylated Hb and increase in fasting plasma insulin levels, as well as maintained pancreatic insulin content to the same level compared with normal rats without affecting pancreatic glucagon content in Zucker diabetic fatty rats.
作用机制 TAK-875 can interact with GPR40 directly through three groups of interactions and form a complex is in an inactive-like state.[1][2]

Fasiglifam 动物研究

Dose Rat: 3 mg/kg - 30 mg/kg[4] (p.o.), 1000 mg/kg[5] (p.o.)
Administration p.o.

Fasiglifam 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01433393 Diabetes Mellitus Phase 3 Completed - Japan ... 展开 >> Kisarazu-shi, Chiba, Japan Matsuyama-shi, Ehime, Japan Fukuoka-shi Nishi-ku, Fukuoka, Japan Kasuga-shi, Fukuoka, Japan Naka-shi, Ibaragi, Japan Tsuchiura-shi, Ibaragi, Japan Takamatsu-shi, Kagawa, Japan Kyoto-shi Fushimi-ku, Kyoto, Japan Nagasaki-shi, Nagasaki, Japan Kashihara-shi, Nara, Japan Kashiwara-shi, Osaka, Japan Osaka-shi Tsurumi-ku, Osaka, Japan Sakai-shi Nishi-ku, Osaka, Japan Shimotsuke-shi, Tochigi, Japan Chiyoda-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan 收起 <<
NCT01585792 Diabetic Patients Phase 3 Completed - Japan ... 展开 >> Fukuoka-shi, Fukuoka, Japan Sumida-ku, Tokyo, Japan 收起 <<
NCT01007097 Diabetes Mellitus, Type 2 Phase 2 Completed - -

Fasiglifam 参考文献

[1]Negoro N, Sasaki S, et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2010 Jun 18;1(6):290-4.

[2]Srivastava A, Yano J, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature. 2014 Sep 4;513(7516):124-7.

[3]Ito R, Tsujihata Y, et al. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. Br J Pharmacol. 2013 Oct;170(3):568-80.

Fasiglifam 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.53mL

1.91mL

0.95mL

19.06mL

3.81mL

1.91mL

Fasiglifam 技术信息

CAS号1000413-72-8
分子式C29H32O7S
分子量 524.63
SMILES Code O=C(O)C[C@@H]1COC2=CC(OCC3=CC(C4=C(C)C=C(OCCCS(=O)(C)=O)C=C4C)=CC=C3)=CC=C12
MDL No. MFCD18251445
别名 Tak-875
运输蓝冰
InChI Key BZCALJIHZVNMGJ-HSZRJFAPSA-N
Pubchem ID 24857286
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry, room temperature

溶解方案 请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案一
方案二
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。